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OBJECTIVES The aim of this study was to evaluate whether the occurrence of the Brugada Syndrome
typical electrocardiogram (ECG) pattern (i.e., right bundle branch block, coved-type
ST-segment elevation, and T-wave inversion in the right precordial leads) is characterized by
a concomitant lengthening of QT intervals in the right precordial leads.
BACKGROUND It has been suggested that the typical ECG pattern of Brugada syndrome is due to a decreased
net inward current during phase 1 of the action potential, which also leads to its prolongation
in the right epicardium.
METHODS Thirty-two subjects (19 males) age 37  15 years with a suspicious baseline ECG, or who
were relatives of Brugada syndrome patients, underwent 12-lead ECG before and after the
administration of flecainide.
RESULTS The flecainide test was negative in 14 and positive in 18 subjects. After flecainide
administration, the positive ECGs were characterized by a greater QT interval corrected for
heart rate (QTc) prolongation in the right precordial leads than that in the negative ECGs
(78.2  35.5 ms vs. 22.0  28.4 ms in V1 and 107.1  43.8 ms vs. 26.7  30.1 ms in V2;
p  0.01), whereas there was no difference in the QTc prolongation in the left precordial
leads (55.2  25.3 ms vs. 35.1  28.1 ms in V5 and 53.1  32.8 ms vs. 27.3  22.4 ms in
V6; p  NS).
CONCLUSIONS In accordance with the electrophysiological background, the typical ECG pattern of Brugada
syndrome is also characterized by a considerable prolongation of the QT interval in right
precordial leads. (J Am Coll Cardiol 2003;42:1632–7) © 2003 by the American College of
Cardiology Foundation
Brugada syndrome is an inherited clinical entity character-
ized by a high risk of sudden cardiac death, by distinct
spontaneous or sodium channel blocker-induced electrocar-
diographic (ECG) findings of right bundle branch block,
ST-segment elevation, and inverted T wave in the right
precordial leads (1–3). It has been suggested that the
underlying mechanism may be a decreased net inward
current or increased net outward current during phase 1 of
the action potential (AP) (3,4) and that the resulting ionic
abnormalities may be responsible for an increase in the
magnitude of the right epicardial AP notch (i.e., stronger
repolarization leading to more negative potential at the
nadir of the notch). This could lead to a reduced availability
of calcium current, resulting in a delay in the emergence of
the second upstroke and in the onset of phase 3 and, at least,
in a prolongation of the AP itself (3).
The aim of this study was to evaluate whether the
occurrence of the typical Brugada syndrome ECG pattern is
characterized by a concomitant lengthening of QT intervals
in the right precordial leads.
METHODS
Study population. Thirty-two of 35 subjects referred to
our Institution for a Brugada syndrome diagnostic work-up
(19 males; mean age, 37  15 years) with a negative or
suspect ECG underwent a flecainide test; the remaining
three had typical baseline ECGs and were excluded. There
were 11 probands: one had a history of cardiac arrest, three
a history of syncope, and seven were identified during
routine examinations. The other 21 subjects (all asymptom-
atic) were recruited during family screenings after the
diagnosis of Brugada syndrome in a family member. Struc-
tural heart disease was ruled out by means of non-invasive
methods (echocardiography and nuclear magnetic reso-
nance), and 13 patients also underwent coronary angiogra-
phy, left and right ventriculography, and biopsy. The study
was approved by our local ethics committee, and all of the
subjects gave their informed consent to participate.
Flecainide test protocol. The evaluations were made in
the morning in a quiet and light-attenuated room. The
subjects were asked to remain resting in a supine position
throughout the procedure. Flecainide was intravenously
infused (2 mg/kg body weight over 10 min), and the
subjects were continuously monitored until 30 min after the
completion of drug administration using a conventional
bedside monitor (Hewlett Packard model 78354C, An-
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dover, Massachusetts). A simultaneous 12-lead ECG
(Hewlett Packard model M1702A) was recorded at a paper
speed of 25 mm/s and an amplitude of 10 mm/mV under
baseline conditions and 5 min after the end of flecainide
administration, when the effect of the drug reaches steady
state (5). The ECGs were considered typical when they had
a coved-type pattern: a terminal r’ wave with a J-point
elevation of2 mm and a slowly descending ST segment in
continuation with a flat or negative T wave in leads V1 to V2
(6). A saddle-type pattern was not considered typical (6).
Typical flecainide-induced ECGs were used to classify the
subjects into positive and negative groups (Fig. 1).
ECG analysis. The 12-lead ECGs were scanned by a flat
scanner (HP ScanJet 5300C, Hewlett Packard) with a
resolution of 600 dots per inch (equivalent to 1 ms per
dot) and then displayed on a monitor. The QRS duration,
QT interval, and the preceding RR interval were measured
using specific software written in Visual Basic 6.0 language
for PC-compatible computers that works with all Windows
operating systems. The software provided the use of semi-
automatic calculation. The ECGs were analyzed by a single
operator and validated by another. As an accurate estimate
of precordial QRS is difficult to obtain in Brugada patients,
its duration was calculated in standard leads from the start
to the end of the QRS complex, and the longest QRS was
considered (7). The QT interval and the QT interval
corrected for heart rate (QTc, Bazett’s formula) were
calculated in V1 to V6 (8). The QT interval was calculated
from the onset of the QRS complex to the end of the T
wave, at the point in which it returned to the isoelectric line
(9). Leads with a small T wave (50 V) were excluded
(10). A detectable deflection after the T wave was consid-
ered a U wave when the interval between the end of the T
wave and the apex of the doubtful deflection was 100 ms
(11). The inter- and intraobserver reproducibilities of the
RR interval, QRS duration, and the QT interval in V1 to V6
were almost perfect (Intraclass Correlation Coefficient
0.97) (12).
Molecular analysis. All screened subjects underwent mo-
lecular genetic analysis. All 28 exons of the SCN5A gene
were amplified by means of polymerase chain reaction
(PCR) using intronic primers from genomic DNA isolated
from the peripheral leukocytes of all of the subjects. The
PCR products underwent single-strand conformation poly-
morphism (SSCP) analysis using precast polyacrylamide
gels (Amersham Pharmacia, Biotech, Uppsala, Sweden),
followed by the direct sequence analysis of aberrant con-
Abbreviations and Acronyms
AP  action potential
ICC  intraclass correlation coefficient
PCR  polymerase chain reaction
QTc  QT interval corrected for heart rate
ROC  receiver operator characteristics
SSCP  single-strand conformation polymorphism
Figure 1. Right and left precordial leads at baseline and after flecainide administration. (A) Shows a patient with a negative test; after flecainide QT is
slightly prolonged in both the right and left precordial leads. (B) Shows a patient with a positive test; note the marked prolongation of QT in the right
precordial leads, which is greater than that observed in the left precordial leads.
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formers (13). In order to increase the probability of detect-
ing the presence of any sequence changes, the SSCP analysis
was carried out at two different temperatures (5°C and
20°C) and three different buffer pH values (7.5, 8.6, and 9.0)
for each exon. A panel of 60 unrelated healthy individuals
(120 chromosomes), coming from the same geographic area
(Southern Italy) was used as a control. Our local ethics
committee approved the study, and written informed con-
sent was obtained from all of the participants.
Statistical analysis. The continuous variables are presented
as mean values SD. Reproducibility of data was evaluated
by means of the intraclass correlation coefficient (ICC) (12).
Thus, ICC  SD2 between /(SD
2
between  SD
2
within). In
particular, reproducibility was considered good if the ICC
was between 0.61 and 0.80 and almost perfect if it was
between 0.81 and 1. QRS durations before and after
flecainide, and the mean post-flecainide changes in dura-
tion, were respectively compared by means of Student t test
for dependent and independent samples. The QTc values
obtained before and after flecainide and the mean changes
in QTc intervals were compared by means of analysis of
covariance using QRS durations as covariates. Sensitivity
was defined as the number of patients with QTc prolonga-
tion after flecainide divided by the number of patients with
QRS-ST-T modification after flecainide. Specificity was
defined as the number of patients without QTc prolonga-
tion after flecainide divided by the number of patients
without QRS-ST-T modification after flecainide. For each
lead, all QTc values were used to construct receiver operator
characteristics (ROC) curve by plotting its sensitivity versus
its 1-specificity. The diagnostic accuracy of the QTc interval
recorded in each precordial lead after flecainide administra-
tion was evaluated using the areas under the ROC curve. A
p value of 0.05 was considered statistically significant.
RESULTS
The flecainide test was negative in 14 subjects (7 males;
mean age, 29 12 years) and positive in 18 (12 males; mean
age, 43  16 years).
The QRS duration and QTc intervals were significantly
prolonged after flecainide administration in both the posi-
tive and negative subjects (Table 1).
The mean prolongations of longest QRS in standard
leads and QTc in V1 and V2 were significantly greater in the
positive than the negative group, whereas no between-group
Table 1. Comparison of Electrocardiographic Parameters Before and After Flecainide Administration in Subjects With Negative and
Positive Test
Negative Test Positive Test
No.
Before
Flecainide
After
Flecainide No.
Before
Flecainide
After
Flecainide
QRS max (ms) 14 95.5  12.2 114.5  16.8* 18 106.8  10.2 132.7  17.8*
QTc (ms)
V1 14 392.2  32.6 414.2  30.2* 18 400.8  36.8 479.0  36.6*
V2 14 381.7  28.5 408.4  39.8* 18 406.2  27.9 513.3  45.1*
V3 14 402.9  37.0 442.6  19.2* 17 409.1  27.2 473.7  44.7*
V4 14 404.6  27.8 443.2  22.7* 18 416.6  26.1 471.2  46.3*
V5 14 407.7  25.9 442.7  21.0* 18 417.4  26.8 472.6  27.8*
V6 14 408.7  28.8 435.9  20.0* 18 416.2  29.3 469.3  26.8*
MeanSD. *p  0.05 vs. before flecainide values.
Figure 2. QRS and QTc changes from baseline recorded in the right and left precordial leads in the negative (white columns) and positive groups (grey
columns). Data expressed as mean values  SE. *p  0.01 vs. negative group; †p  0.01 vs. QTcV5, QTcV6.
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differences were found when QTc prolongation in V5 and
V6 was considered (Fig. 2). Furthermore, in the positive
group, the QTc changes from baseline in the right precor-
dial leads were significantly greater than those in the left
precordial leads (Fig 2). No significant differences between
right and left precordial lead changes were found in the
negative group (Fig. 2).
The areas under the ROC curves obtained from the
post-flecainide QTc in each lead are shown in Figure 3. The
area under the ROC curve of the QTc in V1 was 0.93, that
in V2 0.99, in V3 0.76, in V4 0.70, in V5 0.81, in V6 0.83.
The largest area was that found in V2, and the best cutoff
(460 ms) had a sensitivity of 100% in identifying subjects
with a positive test, a specificity of 93%, and an accuracy of
97%.
During the systematic survey of all of the SCN5A gene
exons, one missense mutation changing the coding from
arginine to histidine (R282H) in exon 7 (14) was identified
in three subjects belonging to the same family: two had an
abnormal flecainide-induced ECG pattern with QTc pro-
longation; the third did not have a positive flecainide-
induced ECG pattern but only a marked QTc prolongation
in V2 (464 ms). This sequence change identified in a single
family was not found in 120 chromosomes of normal
subjects or in the chromosomes of the remaining probands
and family members.
DISCUSSION
The diagnosis of Brugada syndrome depends on the spon-
taneous or flecainide-induced occurrence of right bundle
branch block, coved-type ST-segment elevation, and
T-wave inversion in the right precordial leads (1–3). This
study adds a new element to the typical ECG pattern, that
is, it is always associated with a considerable prolongation of
right ventricular repolarization.
The relevance of our finding comes from the fact that it
Figure 3. (A) Receiver operator characteristic curves obtained from the
post-flecainide QTc in each lead. The value of the QTc interval in V2 has
the greatest accuracy in discriminating negative from positive electrocar-
diograms (ECG) (see text for details). (B) Distribution of QTc intervals in
V2 after flecainide administration. A QTc interval in V2 of 464 ms in
females and 442 ms in males identified a positive ECG with 100%
sensitivity and specificity. Closed circles  females with a positive test;
open circles  females with a negative test; closed triangles  males with
a positive test; open triangles  males with a negative test.
Figure 4. Right and left precordial leads recorded in a patient with a
baseline typical electrocardiogram pattern. The end of T wave in V1 and V2
is illustrated by the arrows.
1635JACC Vol. 42, No. 9, 2003 Pitzalis et al.
November 5, 2003:1632–7 QT Interval and Brugada Syndrome
is in accordance with the electrophysiological changes that
have been hypothesized as occurring in the presence of the
altered ionic currents caused by the disease. In Brugada
syndrome, the inherited predominance of the outward
repolarizing current at the end of phase 1 (3,14,15) exag-
gerates the electrical heterogeneity existing within the ven-
tricular wall in physiological states. Under normal condi-
tions, a different balance between inward and outward
currents makes the notch more prominent in the right than
the left epicardium, and in the epicardium than in the
endocardium (16–19). Given that the greater the baseline
AP notch, the longer the induced AP prolongation, the AP
in Brugada patients should be mainly prolonged in the right
epicardium. The suggested mechanism underlying this phe-
nomenon is the presence of a more marked shift of phase 1
toward more negative potentials; this reduces the availability
of calcium current, leading to delays in the emergence of the
second upstroke and the onset of phase 3 and, therefore, a
marked prolongation of AP duration (20,21).
We suggest that the prolongation of the QT interval in
concomitance with the appearance of coved-type ST-
segment elevation is the electrocardiographic manifestation
of these electrophysiological abnormalities. This interpreta-
tion is supported by the fact that there was a strict
association between the lengthening of the QT interval and
the typical ECG pattern: the QT interval was normal when
the baseline ECG did not show any coved-type ST-
segment elevation, but when flecainide induced the typical
ECG pattern, prolonged repolarization appeared because
the drug unmasks the inherited ionic defect. The prolon-
gation of repolarization after flecainide was mainly evident
in the right precordial leads but, although smaller, could also
be seen in the left. This is in line with cellular electrophys-
iology: inhibition of the sodium current should also prolong
AP duration in the left epicardium—but to a lesser extent
than in the right epicardium (19). On the basis of these
considerations, we suggest that QT prolongation in the
right precordial leads is a specific element of the typical
ECG pattern recorded in Brugada patients, a hypothesis
that is strengthened by the finding that spontaneously
occurring typical ECGs are also characterized by a long
QTc interval in these leads (Fig. 4).
A small post-flecainide prolongation of the QTc interval
was also found in negative ECGs. This may have been due
to drug-induced QRS lengthening (22,23), but we cannot
exclude the possibility that, at least in some subjects, genetic
ionic abnormalities may play a role. A number of mutations
in the SCN5A gene encoding the cardiac sodium channel
alpha-subunit have been causally linked to a percentage of
between 10% and 30% of Brugada patients and their
relatives (24). The finding of QTc prolongation strictly
associated with the typical ECG pattern regardless of the
presence or absence of an SCN5A mutation suggests that
the repolarization phase at surface ECG is prolonged every
time the magnitude of the AP notch increases. This
happens whatever the candidate gene mutations supposed to
be involved in causing abnormal ion channel activation
during phase 1 of the AP. In our series, three subjects were
R282H mutation carriers, as reported by Priori et al. (14):
two had a typical flecainide-induced ECG associated with
marked QTc prolongation in the right precordial leads; in
the third, flecainide induced QTc prolongation in V1 and
V2 (the longest among the negative EGCs) without the
typical ECG features. The association between the R282H
mutation and post-flecainide QT prolongation in the ab-
sence of ST-segment elevation suggests that SCN5A mu-
tation carriers without baseline or flecainide-induced typical
ECG pattern (25) may show a prolonged QT. If this is the
case, mutation carriers with a different expression and,
therefore, different susceptibility to sodium channel inhibi-
tion also have different ECG pictures. In particular, those
characterized by a higher expression would have a typical
flecainide-induced ECG pattern and QT prolongation,
whereas QT prolongation alone may be the result of a lower
expression. This hypothesis is supported by what happens
when increasing sodium current inhibition is produced in
experimental models. A small inhibition is associated with a
prolonged AP, whereas a high level of inhibition is associ-
ated with a marked shortening of the AP (20,21). On the
basis of our results, it can be suggested that the former
electrophysiological modification is responsible for QT
prolongation alone and the latter for coved-type ST-
segment elevation (3). The coexistence of these electrophys-
iological effects justifies the coexistence of both ECG
findings.
These findings might be further explored in future studies
evaluating the usefulness of flecainide-induced QTc prolon-
gation in classifying doubtful ECGs, thus making it possible
to shed new light on the pathophysiology of Brugada
syndrome.
In conclusion, we have demonstrated that the typical
ECG pattern of Brugada syndrome is characterized by
coved-type ST-segment elevation and QT prolongation in
the right precordial leads.
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